רדאר ניסויים קליניים

Participants who present in DKA with conditions that affect neurological function such as:

1. suspected alcohol or drug use,
2. severe head trauma,
3. meningitis, etc., who would not be able to consent/assent for the study.

Participants who present in DKA who are showing signs of altered mental status at time of enrollment.

Other known complicating illness or poorly-controlled chronic illness that is known to affect blood glucose levels and/or electrolyte balance such as:

1. chronic renal disease (requiring hemodialysis),
2. chronic liver disease (with evidence of current hepatic dysfunction,
3. coagulopathy, and/or chronic hepatitis), or
4. severe chronic lung disease (requiring the use of oral steroids).

Use of medications that are known to affect blood glucose levels such as:

1. oral glucocorticoids,
2. Metformin,
3. SGLT2 inhibitors,
4. GLP-1 receptor agonists,
5. DPP-4 inhibitors,
6. thiazolidinediones
7. sulfonylureas, and
8. vasopressors, etc.

Participants who have begun DKA treatment prior to being approached for enrollment and have received more than 6 hours of IV insulin therapy.

Participants who are known to be pregnant.

Participants who have a known diagnosis of type 2 diabetes.

Participants for whom the treating physicians feel a specific insulin regimen is necessary such that patient safety or well-being could be compromised by enrollment into the study.